Pds Biotechnology Corp Stock Current Liabilities
| PDSB Stock | USD 1.09 0.02 1.87% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess PDS Biotechnology's long-term financial health and intrinsic value.
The current year's Total Current Liabilities is expected to grow to about 17.9 M. The current year's Non Current Liabilities Total is expected to grow to about 9.4 M. PDS | Current Liabilities | Build AI portfolio with PDS Stock |
PDS Biotechnology Corp Company Current Liabilities Analysis
PDS Biotechnology's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current PDS Biotechnology Current Liabilities | 4.54 M |
Most of PDS Biotechnology's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PDS Biotechnology Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
PDS Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for PDS Biotechnology is extremely important. It helps to project a fair market value of PDS Stock properly, considering its historical fundamentals such as Current Liabilities. Since PDS Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PDS Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PDS Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
PDS Current Liabilities Historical Pattern
Today, most investors in PDS Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various PDS Biotechnology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of PDS Biotechnology current liabilities as a starting point in their analysis.
PDS Biotechnology Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
PDS Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, PDS Biotechnology Corp has a Current Liabilities of 4.54 M. This is 99.74% lower than that of the Biotechnology sector and 99.16% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.94% higher than that of the company.
PDS Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PDS Biotechnology's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PDS Biotechnology could also be used in its relative valuation, which is a method of valuing PDS Biotechnology by comparing valuation metrics of similar companies.PDS Biotechnology is currently under evaluation in current liabilities category among its peers.
PDS Fundamentals
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 27.43 M | ||||
| Shares Outstanding | 45.71 M | ||||
| Shares Owned By Insiders | 3.08 % | ||||
| Shares Owned By Institutions | 18.11 % | ||||
| Number Of Shares Shorted | 2.44 M | ||||
| Price To Earning | 24.70 X | ||||
| Price To Book | 2.17 X | ||||
| EBITDA | (33.75 M) | ||||
| Net Income | (37.61 M) | ||||
| Cash And Equivalents | 52.98 M | ||||
| Cash Per Share | 1.86 X | ||||
| Total Debt | 21.83 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.34 X | ||||
| Book Value Per Share | 0.49 X | ||||
| Cash Flow From Operations | (35.03 M) | ||||
| Short Ratio | 5.20 X | ||||
| Earnings Per Share | (0.94) X | ||||
| Price To Earnings To Growth | (0.05) X | ||||
| Target Price | 7.5 | ||||
| Number Of Employees | 24 | ||||
| Beta | 1.21 | ||||
| Market Capitalization | 48.91 M | ||||
| Total Asset | 45.36 M | ||||
| Retained Earnings | (182.11 M) | ||||
| Working Capital | 27.97 M | ||||
| Current Asset | 39.11 M | ||||
| Current Liabilities | 4.54 M | ||||
| Net Asset | 45.36 M |
About PDS Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PDS Biotechnology Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PDS Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PDS Biotechnology Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:Check out PDS Biotechnology Piotroski F Score and PDS Biotechnology Altman Z Score analysis. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.